Analyst Price Target is $10.00
▲ +440.54% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Silo Pharma in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 440.54% upside from the last price of $1.85.
Current Consensus is
Buy
The current consensus among 1 polled investment analysts is to buy stock in Silo Pharma. This Buy consensus rating has held steady for over two years.
Silo Pharma. Inc., a developmental stage biopharmaceutical company, develops traditional therapeutics and psychedelic medicine. Its lead program includes SPC-15, an intranasal drug targeting post-traumatic stress disorder (PTSD) and stress-induced anxiety disorders; and SP-26, a ketamine-based loaded implant indicated for fibromyalgia and chronic pain relief. The company's preclinical products include SPC-14 to treat Alzheimer's disease; and SPU-16, a central nervous system homing peptide targeting the central nervous system with indication in multiple sclerosis. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin and ketamine, as well as depression, mental health issues, and neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Read More
